Cited by 626Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?

Open access
Kanekiyo, Takahisa, Xu, Huaxi, Bu, Guojun·2014·Neuron

Abstract

Among the three human apolipoprotein E (apoE) isoforms, apoE4 increases the risk of Alzheimer's disease (AD). While transporting cholesterol is a primary function, apoE also regulates amyloid-β (Aβ) metabolism, aggregation, and deposition. Although earlier work suggests that different affinities of apoE isoforms to Aβ might account for their effects on Aβ clearance, recent studies indicate that apoE also competes with Aβ for cellular uptake through apoE receptors. Thus, several factors probably determine the variable effects apoE has on Aβ. In this Review, we examine biochemical, structural, and functional studies and propose testable models that address the complex mechanisms underlying apoE-Aβ interaction and how apoE4 may increase AD risk and also serve as a target pathway for therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuron.2014.01.045

Cites

165 of 165 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • As LDLR and heparin play critical roles in Aβ clearance and tau aggregation, the ε7 isoform may influence AD pathology through these pathways.

    “As these molecules play critical roles in Aβ clearance and tau aggregation,41,42 the ε7 isoform may influence AD pathology through these pathways.”

    From Association of rare <i>APOE</i> missense variants with Alzheimer's disease in the Japanese population (2025) · cites this paper as [41]

    In “ApoE in Aβ clearance” (page unavailable), the paper says LDLR mediates brain-to-blood Aβ clearance. In “ApoE and Aβ in endocytic trafficking” (page unavailable), it links heparan sulfate proteoglycans to cellular uptake of tau, but does not say that heparin plays a critical role in tau aggregation. The ε7 proposal follows the citation and is the citing authors’ inference. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • ApoE is a crucial factor in development of AD.

    “ApoE is also a crucial factor in the development of AD (5, 6, 31, 32).”
  • APOE binds to cell surface receptors including LDLR, LRP1, VLDLR, and APOER2.

    “APOE binds to cell surface receptors, such as low‐density lipoprotein receptor (LDLR), LDLR‐related protein 1 (LRP1), very low‐density lipoprotein receptor (VLDLR), and apolipoprotein E receptor 2 (APOER2 or LRP8). 2 , 14 , 15”
  • APOE regulates Aβ clearance via LDL receptors and microglia are critical for Aβ clearance.

    “Since APOE regulates Aβ clearance via LDL receptors and microglia are critical for Aβ clearance, 15 we first focused on the role of IDOL in microglia.”
  • Apolipoprotein E4 is the major genetic risk factor for late-onset familial and sporadic Alzheimer's disease.

    “Apolipoprotein (apo) E4, an isoform of the APOE gene in humans, is the major genetic risk factor for late-onset familial and sporadic AD [4–8], which account for most AD cases.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 166 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Kanekiyo, T., Xu, H., & Bu, G.
Affiliations
  • Mayo Clinic (US)
  • Xiamen University (CN)
Corresponding author
Bu, Guojun
Venue
Neuron
Publisher
Elsevier BV
Published
2014-02
Volume
81
Issue
4
Pages
740-754
ISSN
0896-6273 (ISSN-L)
OpenAlex
W2051765035
Cited by
608
References
166
Citations by year
2026: 33 · 2025: 64 · 2024: 59 · 2023: 48 · 2022: 38 · 2021: 63 · 2020: 55 · 2019: 48 · 2018: 42 · 2017: 48 · 2016: 42 · 2015: 43 · 2014: 24
FWCI
6.13
Type
journal article
Language
en
Open access
Locations
  • Neuron (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
Funders
  • Mayo Clinic
  • National Institutes of Health
  • National Institute on Aging (P01AG030128, R01AG044420, R01AG027924, R01AG021173, R01AG031784, RF1AG046205, R01AG046205, R01AG035355)
  • National Institute of Neurological Disorders and Stroke (R01NS046673, P01NS074969)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
apolipoprotein E, APOE ε4, amyloid-beta, Alzheimer's disease, amyloid-beta clearance, apoE receptors, APOE isoforms, amyloid-beta aggregation, cholesterol transport, disease risk, therapeutic target
MeSH terms
Alzheimer Disease, Animals, Apolipoproteins E, Brain, Humans, Neurons, Risk Factors, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review